Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
CVKD
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-1.35
vs -0.04
Q3.23
N/A
-1.05
vs -0.09
Q4.23
N/A
-0.75
vs -0.41
Q1.24
N/A
-1.50
vs -6.62
Q2.24
N/A
-2.25
vs -1.35
Q3.24
N/A
-2.18
vs -1.05
Q4.24
N/A
-2.74
vs -0.75
Q1.25
N/A
-2.09
vs -1.50
Q2.25
N/A
-1.77
vs -2.25
Q3.25
N/A
-1.63
vs -2.18
Sales Growth
YoY
Current
Estimates
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
2.8K vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
-100%
NA vs 2.8K
Q1.25
NA
NA vs NA
Return on Equity
QoQ
Q2.23
-32%
-0.32
vs -1.27
Q3.23
-12%
-0.12
vs -0.32
Q4.23
-15%
-0.15
vs -0.12
Q1.24
-27%
-0.27
vs -0.15
Q2.24
-60%
-0.60
vs -0.27
Q3.24
-71%
-0.71
vs -0.60
Q4.24
-56%
-0.56
vs -0.71
Q1.25
NA
NA
vs -0.56
Institutionnal Ownership
Quote Panel
Key Metrics
businesswire.com
7 hours ago
businesswire.com
8 hours ago
businesswire.com
9 hours ago
prnewswire.com
9 hours ago
Forecast
-61%2026-EPS
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
No Data Available
Relative Strength
CVKD
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.36Â ( 2.74%)
Relative Strenght
Volume Buzz
-79%
Earning Acce
No
Dist 52w H.
41%